Proven efficacy in Dupuytren’s treatment

Xiapex has proven efficacy in the treatment of Dupuytren's contracture. Its efficacy is supported by data gathered from CORD I and CORD II.2,3 These are the largest prospective, placebo-controlled studies conducted in patients with Dupuytren’s disease to date.

The result of CORD I showed that Xiapex reduced the degree of contracture to 5 degrees or less, approximately 30 days after the last injection of the joint, in 64% of the 308 enrolled patients. This compared with the 6.8% of those injected with placebo (P < 0.001).Similar results were seen in CORD II (44.4 % vs 4.8 %; p<0.001).3

Are you a healthcare professional?

Dupuytren’s disease

Peyronie’s disease